• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.程序性细胞死亡受体 1 通路的损伤会增加动脉粥样硬化病变的发展和炎症。
Arterioscler Thromb Vasc Biol. 2011 May;31(5):1100-7. doi: 10.1161/ATVBAHA.111.224709. Epub 2011 Mar 10.
2
Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice.在小鼠中,促动脉粥样硬化免疫反应受PD-1/PD-L途径调控。
J Clin Invest. 2007 Oct;117(10):2974-82. doi: 10.1172/JCI31344.
3
LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.Lag-3、TGF-β 和细胞内 PD-1 抑制途径有助于异基因 BMT 联合抗 CD40L 诱导的 CD8 而非 CD4 T 细胞耐受。
Blood. 2011 May 19;117(20):5532-40. doi: 10.1182/blood-2010-11-318675. Epub 2011 Mar 21.
4
Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.体内CD4和CD8 T细胞介导的同种异体免疫反应中负性T细胞共刺激途径的作用分析
J Immunol. 2005 Jun 1;174(11):6648-56. doi: 10.4049/jimmunol.174.11.6648.
5
Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway.同种异体反应性CD8而非CD4 T细胞的外周删除性耐受依赖于PD-1/PD-L1途径。
Blood. 2008 Sep 1;112(5):2149-55. doi: 10.1182/blood-2007-12-127449. Epub 2008 Jun 24.
6
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.程序性死亡受体 1 配体 1:B7-1 通路在体内抑制致糖尿病效应 T 细胞。
J Immunol. 2011 Aug 1;187(3):1097-105. doi: 10.4049/jimmunol.1003496. Epub 2011 Jun 22.
7
Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo.体内PD-L1和PD-L2通路在调节同种异体反应性CD4(+)和CD8(+) T细胞方面存在显著差异。
Am J Transplant. 2007 Dec;7(12):2683-92. doi: 10.1111/j.1600-6143.2007.01999.x. Epub 2007 Oct 9.
8
PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues.程序性死亡受体1(PD-1)调节淋巴结和组织中自身反应性CD8 + T细胞对抗原的反应。
J Immunol. 2007 Oct 15;179(8):5064-70. doi: 10.4049/jimmunol.179.8.5064.
9
Programmed death-1 pathway limits central nervous system inflammation and neurologic deficits in murine experimental stroke.程序性细胞死亡受体 1 通路限制了实验性卒中小鼠中枢神经系统炎症和神经功能缺损。
Stroke. 2011 Sep;42(9):2578-83. doi: 10.1161/STROKEAHA.111.613182. Epub 2011 Jul 7.
10
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.PD-1:PD-L抑制通路对CD4(+)和CD8(+) T细胞均有影响,且可被白细胞介素-2克服。
Eur J Immunol. 2002 Mar;32(3):634-43. doi: 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9.

引用本文的文献

1
Cytotoxic granules and effector molecules from immune cells in tuberculosis: Mechanisms of host defense and therapeutic potential.结核病中免疫细胞的细胞毒性颗粒和效应分子:宿主防御机制及治疗潜力
Virulence. 2025 Dec;16(1):2542466. doi: 10.1080/21505594.2025.2542466. Epub 2025 Aug 18.
2
The impact of immune checkpoint inhibition on atherosclerosis in cancer patients.免疫检查点抑制对癌症患者动脉粥样硬化的影响。
Front Immunol. 2025 Jul 31;16:1604989. doi: 10.3389/fimmu.2025.1604989. eCollection 2025.
3
Patients with peripheral artery disease demonstrate altered expression of soluble and membrane-bound immune checkpoints.外周动脉疾病患者表现出可溶性和膜结合免疫检查点的表达改变。
Front Immunol. 2025 Jul 21;16:1568431. doi: 10.3389/fimmu.2025.1568431. eCollection 2025.
4
Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitors: Interpreting the Discrepancy Between Clinical Trials and Real-World Data.免疫检查点抑制剂相关的心血管毒性:解读临床试验与真实世界数据之间的差异
Cureus. 2025 Jun 30;17(6):e87049. doi: 10.7759/cureus.87049. eCollection 2025 Jun.
5
Immunotherapy-associated hemostatic abnormalities: bleeding and thrombotic complications.免疫治疗相关的止血异常:出血和血栓形成并发症。
Ann Hematol. 2025 Jul;104(7):3537-3551. doi: 10.1007/s00277-025-06482-z. Epub 2025 Jul 1.
6
Understanding Atherosclerotic Plaque Cellular Composition: Recent Advances Driven by Single Cell Omics.了解动脉粥样硬化斑块的细胞组成:单细胞组学推动的最新进展
Cells. 2025 May 23;14(11):770. doi: 10.3390/cells14110770.
7
Exploring the Emerging Association Between Immune Checkpoint Inhibitors and Thrombosis.探索免疫检查点抑制剂与血栓形成之间新出现的关联。
J Clin Med. 2025 May 15;14(10):3451. doi: 10.3390/jcm14103451.
8
Case Report: Acral vasculitis induced by Immune Checkpoint Inhibitors: a case series and literature review.病例报告:免疫检查点抑制剂诱发的肢端血管炎:病例系列及文献综述
Front Oncol. 2025 May 9;15:1537825. doi: 10.3389/fonc.2025.1537825. eCollection 2025.
9
The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure.免疫检查点蛋白PD-1和CTLA-4在导致心力衰竭的心血管并发症中的作用。
Front Immunol. 2025 Apr 4;16:1561968. doi: 10.3389/fimmu.2025.1561968. eCollection 2025.
10
Immune Checkpoint Inhibitors and Cardiovascular Adverse Events.免疫检查点抑制剂与心血管不良事件
ESC Heart Fail. 2025 Apr 10. doi: 10.1002/ehf2.15281.

本文引用的文献

1
Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF.HIV 特异性 CD8+ T 细胞的转录分析表明,PD-1 通过上调 BATF 抑制 T 细胞功能。
Nat Med. 2010 Oct;16(10):1147-51. doi: 10.1038/nm.2232. Epub 2010 Oct 3.
2
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.靶向 Tim-3 和 PD-1 通路逆转 T 细胞耗竭,恢复抗肿瘤免疫。
J Exp Med. 2010 Sep 27;207(10):2187-94. doi: 10.1084/jem.20100643. Epub 2010 Sep 6.
3
Cardiovascular complications of AIDS.艾滋病的心血管并发症。
Curr Opin Crit Care. 2010 Oct;16(5):408-12. doi: 10.1097/MCC.0b013e32833e10a9.
4
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.抗程序性死亡-1 单药(MDX-1106)治疗难治性实体瘤的 I 期研究:安全性、临床活性、药效学和免疫相关性。
J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1.
5
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.程序性细胞死亡蛋白-1 诱导单核细胞产生白细胞介素-10 可损害 HIV 感染期间 CD4+ T 细胞的活化。
Nat Med. 2010 Apr;16(4):452-9. doi: 10.1038/nm.2106. Epub 2010 Mar 7.
6
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.PD-L1 调节诱导性调节 T 细胞的发育、维持和功能。
J Exp Med. 2009 Dec 21;206(13):3015-29. doi: 10.1084/jem.20090847. Epub 2009 Dec 14.
7
PD-1 and its ligands in tolerance and immunity.PD-1及其配体在免疫耐受与免疫中的作用
Annu Rev Immunol. 2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331.
8
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.化学预防剂可诱导乳腺癌细胞表面程序性死亡受体1配体1(PD-L1)的表达,并促进PD-L1介导的T细胞凋亡。
Mol Immunol. 2008 Mar;45(5):1470-6. doi: 10.1016/j.molimm.2007.08.013. Epub 2007 Oct 24.
9
PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues.程序性死亡受体1(PD-1)调节淋巴结和组织中自身反应性CD8 + T细胞对抗原的反应。
J Immunol. 2007 Oct 15;179(8):5064-70. doi: 10.4049/jimmunol.179.8.5064.
10
Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice.在小鼠中,促动脉粥样硬化免疫反应受PD-1/PD-L途径调控。
J Clin Invest. 2007 Oct;117(10):2974-82. doi: 10.1172/JCI31344.

程序性细胞死亡受体 1 通路的损伤会增加动脉粥样硬化病变的发展和炎症。

Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.

机构信息

Department of Pathology, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, NRB Rm 752N, 77 Ave Louis Pasteur, Boston, MA 02115, USA.

出版信息

Arterioscler Thromb Vasc Biol. 2011 May;31(5):1100-7. doi: 10.1161/ATVBAHA.111.224709. Epub 2011 Mar 10.

DOI:10.1161/ATVBAHA.111.224709
PMID:21393583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3104026/
Abstract

OBJECTIVE

Programmed cell death-1 (PD-1) is a member of the CD28 superfamily that delivers negative signals on interaction with its 2 ligands, PD-L1 and PD-L2. We studied the contribution of the PD-1 pathway to regulation of T cells that promote atherosclerotic lesion formation and inflammation.

METHODS AND RESULTS

We show that compared with Ldlr-/- control mice, Pd1-/-Ldlr-/- mice developed larger lesions with more abundant CD4+ and CD8+ T cells and macrophages, accompanied by higher levels of serum tumor necrosis factor-α. Iliac lymph node T cells from Pd1-/-Ldlr-/- mice proliferated more to αCD3 or oxidized low-density lipoprotein stimulation compared with controls. CD8+ T cells from Pd1-/-Ldlr-/- mice displayed more cytotoxic activity compared with controls in vivo and in vitro. Administration of a blocking anti-PD-1 antibody increased lesional inflammation in hypercholesterolemic Ldlr-/- mice with more lesional T cells and more activated T cells in paraaortic lymph nodes. The changes in lesional T-cell content when PD-1 was absent or blocked were also observed in bone marrow chimeric Ldlr-/- mice lacking PD-L1 and PD-L2 on hematopoietic cells.

CONCLUSIONS

PD-1 has an important role in downregulating proatherogenic T-cell responses, and blockade of this molecule for treatment of viral infections or cancer may increase risk of cardiovascular complications.

摘要

目的

程序性细胞死亡受体-1(PD-1)是 CD28 超家族的成员,与 2 种配体 PD-L1 和 PD-L2 相互作用时传递负信号。我们研究了 PD-1 通路对促进动脉粥样硬化病变形成和炎症的 T 细胞的调节作用。

方法和结果

与 Ldlr-/- 对照组小鼠相比,我们发现 Pd1-/-Ldlr-/- 小鼠的病变更大,CD4+和 CD8+T 细胞和巨噬细胞更丰富,伴有更高水平的血清肿瘤坏死因子-α。与对照组相比,Pd1-/-Ldlr-/- 小鼠的髂淋巴结 T 细胞对 αCD3 或氧化型低密度脂蛋白刺激的增殖更多。与对照组相比,Pd1-/-Ldlr-/- 小鼠的 CD8+T 细胞在体内和体外显示出更强的细胞毒性活性。在高胆固醇血症的 Ldlr-/- 小鼠中,给予阻断性抗 PD-1 抗体可增加病变炎症,表现为病变 T 细胞增多,腹主动脉淋巴结中 T 细胞更活跃。在缺乏造血细胞上的 PD-L1 和 PD-L2 的骨髓嵌合 Ldlr-/- 小鼠中,当 PD-1 缺失或被阻断时,病变 T 细胞含量的变化也被观察到。

结论

PD-1 在下调促动脉粥样硬化性 T 细胞反应中具有重要作用,阻断该分子用于治疗病毒感染或癌症可能会增加心血管并发症的风险。